Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · IEX Real-Time Price · USD
2.070
-0.040 (-1.90%)
At close: Jul 19, 2024, 4:00 PM
2.050
-0.020 (-0.97%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Leap Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Leap Therapeutics stock have an average target of 10.4, with a low estimate of 5.50 and a high estimate of 17.5. The average target predicts an increase of 402.42% from the current stock price of 2.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LPTX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +286.47% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5.5 | Strong Buy | Maintains | $7 → $5.5 | +165.70% | May 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +238.16% | Mar 19, 2024 |
| Baird | Baird | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +334.78% | Mar 19, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +479.71% | Nov 20, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.75
from -3.98
EPS Next Year
-1.58
from -1.75
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 6.3M | 110.1M | 216.9M |
| Avg | n/a | n/a | 3.1M | 36.2M | 83.8M |
| Low | n/a | n/a | n/a | n/a | 24.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 3,497.7% | 499.3% |
| Avg | - | - | - | 1,082.9% | 131.6% |
| Low | - | - | - | - | -31.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.61 | -1.11 | -0.92 | -0.25 | 0.57 |
| Avg | -1.75 | -1.58 | -1.56 | -1.40 | -1.00 |
| Low | -1.82 | -1.89 | -2.15 | -2.00 | -1.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.